CTRI/2020/04/024680Other3 期
A Phase III, Multicenter, Sham-Controlled, Randomized, Double-Masked Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 µg DE-109 for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye. - LUMINA
试验速览
- 阶段
- 3 期
- 状态
- Other
- 入组人数
- 47
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Non-Infectious Active Uveitis of the Posterior Segment
排除标准
- •Females who are pregnant, nursing or planning a pregnancy.
- •Confirmed or suspected infectious uveitis.
研究者
相似试验
进行中（未招募）
1 期
A phase III clinical trial to determine the safety and effectiveness ofNT-501, an implant in the eye shown to reduce the rate of progression of Macular Telangiectasia type 2Macular Telangiectasia type 2EUCTR2017-003260-12-DEeurotech Pharmaceuticals Inc.112
进行中（未招募）
不适用
A study to assess the efficacy and safety of ON 01910.Na in combination with Gemcitabine vs. Gemcitabine alone in patients with a previously untreated metastatic pancreatic cancer.Metastatic Pancreatic CancerMedDRA version: 15.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864EUCTR2012-003547-29-HUOnconova Therapeutics Inc.364
进行中（未招募）
3 期
A clinical trial to study the safety and efficacy of ON 01910.Na in combination with gemcitabine in patients with previously untreated Metastatic pancreatic cancerCTRI/2011/06/001837Onconova Therapeutics Inc400
进行中（未招募）
不适用
A study to assess the efficacy and safety of ON 01910.Na given by continuous intravenous infusion for 72 hours every other week in patients with a blood disease who have failed, or are resistant to, or intolerant to Azacitidine or Decitabine treatments.EUCTR2010-019755-21-BEOnconova Therapeutics Inc.270
进行中（未招募）
不适用
A study to assess the efficacy and safety of ON 01910.Na given by continuous intravenous infusion for 72 hours every other week in patients with a blood disease who have failed, or are resistant to, or intolerant to Azacitidine or Decitabine treatmentsMyelodysplastic syndrome with excess blastsMedDRA version: 14.1Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019755-21-ITONCONOVA THERAPEUTICS270